Every Form 4 that Faeth Therapeutics, Inc. (FTH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTH filings page.
Faeth Therapeutics, Inc. (FTH) reported that director Karen H. Vousden received a stock option grant for 25,000 shares of common stock on September 11, 2026. The option has an exercise price of $37.44 per share, expires on September 10, 2036, and vests in 36 equal monthly installments through September 11, 2029, contingent on her continued service. No transactions were reported under a Rule 10b5-1 trading plan.
Faeth Therapeutics, Inc. granted PAO Josiah Craver a performance-based stock option covering 30,824 shares of common stock at an exercise price of $28.37 per share. The option becomes exercisable only if the average Nasdaq closing price reaches $70.00 over 30 consecutive days and at least one year has passed, and is forfeited if the stock price hurdle is not achieved by the fourth anniversary or not met in connection with a qualifying Change in Control. Following this award, Craver holds 30,824 of these options directly.
Faeth Therapeutics, Inc. granted President and CEO Anand Kiran Parikh a performance-based stock option covering 398,018 shares of common stock at a $28.3700 exercise price, expiring in 2036. The option vests only if a sustained $70.00 stock-price hurdle and time-and-service conditions are met. In a qualifying Change in Control where per-share consideration is at least $70.00, it vests in full; if the $70.00 hurdle is not achieved by the fourth anniversary of grant, or not deemed achieved in connection with a Change in Control, the option is forfeited.
Faeth Therapeutics, Inc. Chief Financial Officer Brian C. Stephenson, through the Brian Stephenson Revocable Trust, reported open-market purchases of a total of 13,634 shares of common stock over three days. On June 29 and 30, 2026, and July 1, 2026, the trust bought multiple blocks of shares at weighted average prices disclosed in the filing, including 4,400 shares at $23.40 and 4,255 shares at $24.98. Following the latest transaction, the trust holds 46,688 shares of Faeth Therapeutics common stock. The footnotes state that Stephenson is the sole trustee of the revocable trust, with sole voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.
Faeth Therapeutics, Inc.’s Chief Financial Officer Brian C. Stephenson reported multiple indirect open-market purchases of the company’s common stock. Over June 24 and June 26, 2026, a revocable trust associated with him bought a total of 15,641 shares at prices ranging from about $23.61 to $27.77 per share. Following these transactions, the trust held 33,054 shares of Faeth Therapeutics common stock. The shares are held by the Brian Stephenson Revocable Trust, where he is sole trustee with sole voting and investment power, while he disclaims beneficial ownership except to the extent of his pecuniary interest.
Faeth Therapeutics, Inc. Chief Financial Officer Brian C. Stephenson, through the Brian Stephenson Revocable Trust, reported a series of open-market purchases of the company’s common stock. Over June 22–23, 2026, the trust bought a total of 17,413 shares in eight separate transactions.
The reported weighted average purchase prices ranged from about $19.5765 to $26.31 per share across those trades. All holdings reported in this filing are indirect, held by the revocable trust for which Stephenson serves as sole trustee with sole voting and investment power, and amount to 17,413 shares after these transactions.
Faeth Therapeutics, Inc. President and CEO Anand Kiran Parikh increased his direct stake through option exercises and an open-market stock purchase. He exercised employee stock options to acquire 53,465 shares of common stock at $1.16 per share and bought an additional 2,806 shares in the open market at $19.76 per share, all on June 22, 2026. Following these transactions, he directly owns 817,699 shares of Faeth Therapeutics common stock.